micro-community-banner
 
  • Saved

December 02, 2024
Refractory Burkitt Lymphoma: Diagnosis and Interventional Strategies - PubMed

Refractory Burkitt Lymphoma: Diagnosis and Interventional Strategies - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38510818/

Despite excellent results in frontline therapy, particularly in pediatric age, refractory Burkitt lymphoma still remains a therapeutic challenge, with dismal outcome. The prognosis is very poor, ranging from less than...

Refractory Burkitt lymphoma has a poor prognosis, with survival rates under 40%. Limited data hinder treatment conclusions, but new targeted drugs and stem cell transplants show potential for improving outcomes.

Profile Image
  • Saved

November 26, 2024
American Society of Hematology Annual Meeting 2024

The American Society of Hematology (ASH) is hosting its 66th annual meeting and exposition from Dec. 7 to 10, 2024, in San Diego and online. ASH, the world’s largest professional society of clinicians and scientists dedicated to conquering blood diseases, presents the annual meeting as the most comprehensive hematology event of the year.

Click above to access our conference preview.

  • Saved

November 25, 2024
Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis - PubMed

Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38238443/

Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome driven by pathologic activation of cytotoxic T-lymphocytes and macrophages. Despite advances in diagnostics and management, adult patients with lymphoma-associated HLH (LA-HLH) harbor...

Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH) has poor prognosis, with a median survival of 5.1 months. Elevated soluble CD25 levels >10,000 U/ml indicate unfavorable survival, requiring timely diagnosis and lymphoma-specific treatment.

Profile Image
  • Saved

November 25, 2024
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies - PubMed

Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37907724/

Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic approach for the treatment of patients with chemotherapy-refractory or relapsed blood cancers, including acute lymphoblastic leukaemia, diffuse large...

This review discusses resistance mechanisms to CAR-T cell therapies in blood cancers, including CAR-T dysfunction, tumor resistance, and immunosuppressive microenvironment, and highlights strategies to overcome these challenges.

Profile Image
  • Saved

November 18, 2024
Cutaneous T-cell lymphoma with CNS involvement: a case series and review of the literature - PubMed

Cutaneous T-cell lymphoma with CNS involvement: a case series and review of the literature - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/37877303/

Cutaneous T-cell lymphoma (CTCL) is a rare hematologic malignancy that traditionally presents with cutaneous lesions, though metastases are not uncommon in progressive disease. We describe four cases of CTCL with...

Four CTCL cases with CNS involvement showed a median 5.4-year progression to metastasis. Survival post-metastasis averaged 160 days, with some remission after CNS-directed therapy, highlighting the need for vigilant monitoring.

Profile Image